The main country of operation and country of incorporation is the UK. Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody®, Moditope® and AvidiMab™ platforms. In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against SARS-Cov-2, the virus that causes COVID-19.

The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to reject or kill the growing tumour.

The information on this web site is being disclosed for the purposes of AIM Rule 26 and was last updated on 10 August 2021.